Mizuho raised the firm’s price target on Cytokinetics (CYTK) to $103 from $99 and keeps an Outperform rating on the shares. The analyst updated models in the biotechnology group following the Q3 reports. Cytokinetics shares are “feeling washed out here,” the analyst tells investors in a research note. The firm sees a potential launch of aficamten in obstructive hypertrophic cardiomyopathy in 2025 and models for $3.5B in peak worldwide unadjusted sales.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CYTK:
- Bayer Secures Deal for Cytokinetics’ Heart Drug in Japan
- Cytokinetics partnership demonstrates value of aficamten, says JMP Securities
- Cytokinetics, Bayer enter collaboration and license pact for aficamten in Japan
- Cytokinetics announces initiation of Phase 1 study of CK-089
- Molson Coors upgraded, Rivian downgraded: Wall Street’s top analyst calls
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
